Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2833576 | 0.91 | GAA (0.41) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2840144 | 0.90 | ALDH1A1 (0.44) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2838723 | 0.90 | SMN1; SMN2 (0.43) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2833118 | 0.90 | KMT2A (0.43) | SMN1; SMN2LMNAMAPK1ALDH1A1KDM4E | |
| SCHEMBL2843168 | 0.88 | SMN1; SMN2 (0.42) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2838828 | 0.86 | SMN1; SMN2 (0.41) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2839485 | 0.85 | PTGS2 (0.41) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2843174 | 0.84 | SMN1; SMN2 (0.40) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL2836391 | 0.84 | SMN1; SMN2 (0.40) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 | |
| SCHEMBL5246526 | 0.84 | PDE5A (0.42) | GAASMN1; SMN2LMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | claimed |
| EP-1590352-B1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL LAB (ES) | 2007-06-27 | — | — | EP | claimed |
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | claimed |
| EP-1590352-A1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-02 | — | — | EP | claimed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | claimed |
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| US-7662814-B2 | 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-02-16 | — | — | US | disclosed |
| CN-100582112-C | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA | 2010-01-20 | — | — | CN | disclosed |
| EP-1590352-B1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL LAB (ES) | 2007-06-27 | — | — | EP | disclosed |
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-10-12 | — | — | US | disclosed |
| CN-1761671-A | 4-aminothieno [2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors | ALMIRALL PRODESFARMA SA (ES) | 2006-04-19 | — | — | CN | disclosed |
| EP-1590352-A1 | 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | Almirall Prodesfarma, S.A. (ES) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004065391-A1 | 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229306-A1 | 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors | PDE7B, PDE7A, PDE3A | GAA 502/4885SMN1; SMN2 1122/4885LMNA 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.